PFS according to any hematologic response to therapy (at least partial response or better), landmark analysis at 3 months. (A) PFS according to response to therapy in the non–IgM-AL previously treated patients. (B) PFS according to response to therapy in the IgM-AL previously treated patients. Overall survival according to any hematologic response to therapy (at least partial response or better), landmark analysis at 3 months. (C) Overall survival according to response to therapy in the non–IgM-AL previously treated patients. (D) Overall survival according to response to therapy in the IgM-AL previously treated patients.